Allergan PLC. (AGN) Shares Sold by Sawtooth Solutions LLC
Sawtooth Solutions LLC lessened its stake in Allergan PLC. (NYSE:AGN) by 17.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,376 shares of the company’s stock after selling 725 shares during the period. Sawtooth Solutions LLC’s holdings in Allergan PLC. were worth $821,000 at the end of the most recent quarter.
A number of other large investors also recently bought and sold shares of AGN. Veritas Asset Management LLP bought a new stake in Allergan PLC. in the 1st quarter worth approximately $761,339,000. Iridian Asset Management LLC CT grew its position in Allergan PLC. by 141.3% in the 1st quarter. Iridian Asset Management LLC CT now owns 1,283,833 shares of the company’s stock worth $306,733,000 after purchasing an additional 751,848 shares during the period. Renaissance Technologies LLC bought a new stake in Allergan PLC. in the 1st quarter worth approximately $124,255,000. Blue Ridge Capital L.L.C. grew its position in Allergan PLC. by 24.1% in the 1st quarter. Blue Ridge Capital L.L.C. now owns 1,909,900 shares of the company’s stock worth $456,313,000 after purchasing an additional 370,400 shares during the period. Finally, Harbour Capital Advisors LLC grew its position in Allergan PLC. by 21,412.3% in the 2nd quarter. Harbour Capital Advisors LLC now owns 345,917 shares of the company’s stock worth $1,423,000 after purchasing an additional 344,309 shares during the period. 82.02% of the stock is owned by institutional investors and hedge funds.
Allergan PLC. (AGN) opened at 210.00 on Thursday. The stock has a market cap of $70.20 billion, a PE ratio of 6.40 and a beta of 1.18. The company’s 50 day moving average is $229.79 and its 200-day moving average is $236.07. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80.
Allergan PLC. (NYSE:AGN) last released its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.95 by $0.07. The company had revenue of $4.01 billion for the quarter, compared to analyst estimates of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The firm’s revenue was up 8.8% on a year-over-year basis. During the same quarter last year, the business earned $3.35 earnings per share. Equities research analysts forecast that Allergan PLC. will post $16.25 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Friday, September 15th. Investors of record on Friday, August 18th were given a dividend of $0.70 per share. The ex-dividend date of this dividend was Wednesday, August 16th. This represents a $2.80 annualized dividend and a yield of 1.33%. Allergan PLC.’s dividend payout ratio is presently 9.95%.
A number of equities research analysts have commented on the stock. Mizuho reaffirmed a “buy” rating and issued a $267.00 target price on shares of Allergan PLC. in a research report on Wednesday, August 2nd. Royal Bank Of Canada set a $285.00 target price on shares of Allergan PLC. and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Wells Fargo & Company lifted their target price on shares of Allergan PLC. to $278.00 and gave the stock an “outperform” rating in a research report on Thursday, August 3rd. Deutsche Bank AG reaffirmed a “buy” rating and issued a $273.00 target price (up previously from $265.00) on shares of Allergan PLC. in a research report on Monday, July 17th. Finally, BidaskClub raised shares of Allergan PLC. from a “hold” rating to a “buy” rating in a research report on Saturday, June 24th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $273.34.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.